ENHANCEMENT OF TUMOUR GROWTH as a result of the interaction between tumour and lymphoid cells has been reported in a variety of experimental systems (Fidler, 1973 (Fidler, , 1974 Ilfeld et al., 1973; Prehn, 1972) . The growth of the 3LL tumour of spontaneous origin and of some chemically induced fibrosarcomas was enhanced by lymphocytes of tumour-bearing mice (Umiel & Trainin, 1974; Gabizon et al., 1976; Manor et al., 1976) . In addition, tumour-enhancing lymphocytes from mice bearing a chemically induced fibrosarcoma were found to abolish the activity of tumour-inhibiting lymphocytes when mixed together . The tumour-enhancing effect can also be mediated by lymphoid cells of normal mice, as shown in several instances. Deckers et al. (1971) reported facilitation of tumour growth by normal spleen cells. The development of lung metastases was stimulated when lymphoid cells from normal and tumour-bearing mice were mixed with B-16 tumour cells before injection (Fidler, 1974) . Enhanced growth of the 3LL carcinoma was induced with spleen T cells (Umiel & Trainin, 1974 ) and thymus cells (Umiel et al., 1978) of normal mice. Recently enhancement of YAC lymphoma cells by normal spleen cells in the Winn assay has been reported by Gillette et al. (1978) .
The significance of these data for the role of lymphocytes, and more specifically of T cells, in the growth of primary tumours remains uncertain. The reduced growth of some primary tumours in Tcell-depleted hosts (Gillette & Fox, 1975) may be related to the lack of tumourenhancing T-cell activity. Data on the development of spontaneous tumours in nude mice (Rygaard & Povlsen, 1976) seem to be compatible with a tumourenhancing activity of T cells. The immunostimulatory effects on tumour growth have been extensively studied by Prehn (1976) , who has postulated that the development of incipient tumours is actually stimulated by the immune response. Understanding of the mechanisms by which lymphocytes enhance tumour growth will probably help to evaluate the role of this phenomenon in the hosttumour relationship. In the present study, we have investigated some aspects of the enhancement of tumour growth by lymphocytes from normal mice, including the type of lymphocyte involved. We have examined here the phenomenon of enhancement with the early transplantation generations of a syngeneic, T-cell-derived, radiation-induced lymphoma.
MATERIALS AND METHODS
Animals-Two-to 4-month-old inbred mice from the Animal Breeding Centre at the Weizmann Institute of Science were used throughout these experiments. The strains used were BALB/c (H-2d), C57BL/6 (H-2b), BALB.B (H-2b) and (BALB/c x C57BL/6)Fi, as well as homozygous (nu/nu) and heterozygous (nu/ +) nude athymic mice with the BALB/c genotype.
Tumour.-The tumour used in these experiments was a lymphoma induced by weekly fractionated irradiation (1.7 Gy x 4) in BALB/c mice, kindly provided by Professor N. Haran-Ghera (Weizmann Institute, Rehovot). This lymphoma was kept frozen after induction and then thawed, and used for this study during the first 15 serial transplantations in syngeneic mice. After s.c. injection, it grows locally as a solid nodule with a volumedoubling time of 2 days up to a size of 12 mm. The TD50 in syngeneic BALB/c mice is between 103 and 5 x 103 lymphoma cells ( Figure) . Metastases mainly develop in the spleen, where they can be demonstrated about 1 week after the local tumour becomes palpable, by the growth of tumours from transplants of spleen cells into syngeneic recipients. Liver and lymph nodes are infiltrated later during the course of tumour growth. All the lymphoma cells are sensitive to treatment with anti-0 serum plus complement, indicating that it is a T-cell-derived lymphoma. As shown in Table I , a cell-free extract of this lymphoma prepared as described by HaranGhera et al. (1977) was found to be leukaemogenic after intrathymic injection in irradiated recipients, indicating the presence of an oncogenic virus in the lymphoma cells.
Preparation of cell suspensions.-Spleens, thymuses or lymph nodes were aseptically removed, and cell suspensions prepared by pressing the organ through a fine stainlesssteel mesh into cold Dulbecco's modified Eagle's medium (MEM).
Lymphoma cell suspensions were prepared as follows: the local tumour was aseptically removed from donor animals and the necrotic Anti-0 serum.-The serum was produced following Reif and Allen's procedure (1966) of repeated injections of C3H/eB thymocytes into AKR/J mice. Before use, it was absorbed in a liver powder prepared from C3H/eB mice. The resulting antiserum killed all the thymocytes at a 1: 64 dilution. For the anti-0 treatment, cells were incubated in an ice bath for 1 h with the antiserum, then washed and reincubated with guinea-pig complement (lyophilized complement, GIBCO) for 30 min at 37TC. Control cells were incubated with normal AKR/J serum and complement.
Peanut agglutinin cell fractionation.
Separation of thymus cells with peanut agglutinin (PNA) was performed according to the method of Reisner et al. (1976) . Briefly, 108 cells in 0-25 ml of PBS were mixed with 1 mg of PNA in 0-25 ml in a small Falcon plastic tube and left at room temperature for 10 min. The mixture was then gently layered with a Pasteur pipette on the top of a 50% FCS solution in PBS. When the agglutinated fraction settled on the bottom of the tube, it was carefully aspirated with a Pasteur pipette. The upper layer of non-agglutinated thymocytes was removed with a Pasteur pipette into another tube. The lectin was removed from both fractions by a 10min incubation in 2 ml of 0-3M (Winn, 1961 Table I ) and because tumour cells derived from a mixture of irradiated lymphoma cells and (BALB/c x C57BL/ 6)F1 lymphocytes grew in BALB/c hosts and were negative for the H-2b marker as tested by anti-H-2b and complement cytotoxicity (data not shown).
In additional experiments, we investigated whether tumour enhancement was detectable in immunosuppressed hosts. For this purpose, mice received wholebody irradiation (6 Gy) and were subsequently challenged with lymphoma cells with or without thymus cells. As seen in Table IV , irradiation produced no significant change in the number of tumour takes and time to tumour appearance in mice injected with tumour alone. More- (Umiel & Trainin, 1974; (Gabizon et al., 1976; Small, 1977) . It was important, therefore, to check whether spleen T cells are involved in the enhancement of lymphoma growth in the present experimental model. The results presented in Table VI indicate that treatment with anti-6 serum totally abolished the enhancing effect of spleen cells from normal mice, and that spleen cells from athymic (nu/nu) mice were significantly less effective than spleen cells from their heterozygous littermates (nu/ + ) in tumour enhancement. These results, together with the enhancing activity of thymus cells (see Table II , point to a predominant role of thymusderived cells in the enhancement of lymphoma growth.
Maturity and radiation-8en8itivity tumour-enhancing lymphocytes of An attempt was made to characterize some features of the tumour-enhancing lymphocytes. Thymus cells can be separated into 2 subpopulations by peanut agglutinin (PNA) (Reisner et al., 1976 ..
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tures of irradiated lymphoma cells and iation on the lymphoid cells might be explained by an of lymphoid enhancing effect of the latter on a small own in Table remaining injection of as few as 102 lymphoma cells led to 100% tumour incidence when lymphoid cells were added in the inoculum (Table II) . The possibility of a helper effect on the repair capacity of sublethally damaged tumour cells must also be considered, especially since cell-to-cell contacts, which are known to influence the repair process of sublethal injury (Durand & Sutherland, 1972) may occur between lymphoma and lymphoid cells. Our experiments with anti-6 serum, and with spleen cells from nude mice, indicate a predominant role of T cells in the enhancement of lymphoma growth. The fractionation of thymocytes with peanut agglutinin further indicates that a subpopulation of immature T cells, rather than the whole thymus-cell population, is responsible for the tumour-enhancement effect, suggesting that the tumour-enhancing properties of T cells are cancelled out during maturation. These results are similar to those of Umiel et al. (1978) with other tumours.
The link between immature T lymphocytes and tumour-enhancement is further supported by the experiments of Small (1979) in which TdT activity, a marker of early thymocytes (Barton et al., 1976) was increased in spleen cells of tumour-bearing mice with tumour-enhancing activity. The finding that peripheral lymphnode cells from normal mice showed no tumourenhancing activity is in agreement with the high level of maturation and immunocompetence of lymphnode T cells (Trainin et al., 1979) .
We have shown previously that the enhancing effect of spleen cells from mice bearing a chemically induced fibrosarcoma was not tumour specific (Gabizon et al., 1976) . Together with this, the present observations indicate that a non-sensitized lymphoid population is capable of tumour enhancement, suggesting that a process of specific immunological recognition is not necessarily involved in tumour enhancement. Yet tumour antigens could interact wA'ith potentially tumour-enhancing lymphoid cells in situ after inoculation of 40 the lymphoid-tumour-cell mixture. However, the lack of difference in the enhancing effects of lymphoid cells of different genetic origin (Table V) argues against the relevance of immunological recognition phenomena. Tumour enhancement by allogeneic, as well as syngeneic, lymphocytes has been shown in other experimental models, including spleen cells of tumour-bearing hosts (Manor et al., 1976) and in vitro tumour-sensitized lymphocytes (Small & Trainin, 1975) .
The enhancing effect of lymphoid cells was abrogated by irradiation, indicating that tumour enhancement is not due to a simple feeder effect of dead or irradiated cells similar to the Revesz effect (Revesz, 1958) but to an active process of living cells. In addition, we have found no enhancement of lymphoma growth with supernatants of lymphoid cells (data not shown). It is not clear whether tumour enhancement involves suppression of host resistance, or a direct stimulation of tumour cells by transferred lymphocytes. have presented evidence for the existence of a suppressor, radiosensitive spleen T cell in normal and tumour-bearing mice, which enhances tumour growth. However, the possibility of an immunostimulatory effect was not totally discarded . As shown in this paper, the fact that lymphoid cells could still enhance tumour growth in radiation-immunosuppressed animals is against a suppressive mechanism. A similar result was reported by Carnaud et al. (1974) with another tumour model, suggesting tumour stimulation by enhancing lymphoid cells. The nature of a putative stimulatory interaction between lymphoma and T cells has not been investigated, but a specific response of this T-cell-derived tumour to growth factors of T-cell origin (Morgan et al., 1976) should be considered.
The phenomenon of tumour enhancement may be especially relevant to lymphomas rather than other solid, nonlymphoma tumours. Most mouse lymphomas originate and metastasize in the vicinity of large concentrations of lymphoid cells, including T cells. There is a possibility that small nests of transformed cells are stimulated to proliferate and grow into overt clinical disease in environments such as the thymus by a similar interaction to that found in the present experiments.
